Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI). Randomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies: * Study group: reduced stent PCI strategy (DCB-based) * Control group: conventional PCI strategy (DES-based).

Who May Be Eligible (Plain English)

Who May Qualify: \- Patients presenting with STEMI and indication to undergo pPCI. Who Should NOT Join This Trial: - Life expectancy \<1 year due 1 to non-cardiac disease. - Inability to provide willing to sign a consent form. - Cardiogenic shock. - Left ventricular ejection fraction \<15%. - Left main disease. - Stent thrombosis - Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions). - Patients with chronic total occlusions. - Untreatable coronary disease. - Non-identified culprit lesion. - Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: \- Patients presenting with STEMI and indication to undergo pPCI. Exclusion Criteria: * Life expectancy \<1 year due 1 to non-cardiac disease. * Inability to provide informed consent. * Cardiogenic shock. * Left ventricular ejection fraction \<15%. * Left main disease. * Stent thrombosis * Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions). * Patients with chronic total occlusions. * Untreatable coronary disease. * Non-identified culprit lesion. * Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.

Treatments Being Tested

DEVICE

Primary PCI

Coronary percutaneous revascularization

Locations (15)

Hospital Universitario Y Politecnico La Fe
Valencia, Valencia, Spain
Consorcio Hospitalario Provincial de Castellon
Castelló, Spain
Hospital General Universitario de Elche
Elche, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario de La Princesa
Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
Hospital Universitario Regional de Malaga
Málaga, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Hospital Universitari Joan Xxiii de Tarragona
Tarragona, Spain
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
Hospital Clinico Universitario de Valladolid
Valladolid, Spain
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain